To explain som e of the effects of prenatal glucocorticoid treatment on lung function, surfactant paramet ers in the airway specimens of ventil ator-dependent preterm infants were analyzed . In this double -blind study, the mother s of these infants had received dexam ethasone (DEX) or placebo prenatally. Human surfactant was give n for the treatment of moderate to severe respiratory distress syndrom e. Seventy-six preterm infants with mean gestational age of 29 wk and mean birth weight of 1137 g wer e studied. The concentrations of surfactant comp onents in epithelial lining fluid (ELF) were analyz ed, and the surfac e activity was measured using a pulsating bubble meth od. Prenat al DEX treatment increased the responsiveness to exogenous surfactant and decreased the seve rity of respiratory failure durin g the first day of life. The treatment had no effect on the concentrations of surfactant phospholipid s that were generally high. Prenat al DEX treatment incr eased the association between phospholipid conc entration in ELF and the degre e of respir atory failure . Prenatal DEX improved the surface activity of surfactant isolated from airway speci mens and tended to increase the ratio of surfactant protein A to phosph atidylcholin e among recipients of exogenous surfactant. A subgro up of infants , offspring of Several randomized studies have shown that prenatal glucocorticoid treatment before preterm delivery improves survival and decreases the incidence of RDS in preterm infants (1). Likewise, treatment with both natural and synthetic surfactants decreases the mortality of very low birth weight infants and the severity of RDS (2). In newborn infants with RDS, exogenous surfactant therapy improves gas exchange, functiona l recidual capacity, and dynamic compliance (3). A retrospective analysis of surfact ant trials suggests that the combination therapy of prenatal glucocorticoid and exogenous Received December 27, 1994; accepted May 9, 1995 676 moth ers with severe hypert ension had an abnormally low concentration of surfactant protein A and a poor outcome, despite prenat al DEX treatm ent or surfactant sub stitution. Prenatal DEX decreased the concentration of nonsedim entable proteins in ELF and decreased the inhibition of surface activity by these protein s. Our results indicate that imp roved surfactant function during the first day of life explains some of the beneficial pulm onary effects of prenatal glucocorticoid treatment in preterm infants who are ven tilator-depe ndent. (Pediatr Res 38: 676-684, 1995) 
To explain som e of the effects of prenatal glucocorticoid treatment on lung function, surfactant paramet ers in the airway specimens of ventil ator-dependent preterm infants were analyzed . In this double -blind study, the mother s of these infants had received dexam ethasone (DEX) or placebo prenatally. Human surfactant was give n for the treatment of moderate to severe respiratory distress syndrom e. Seventy-six preterm infants with mean gestational age of 29 wk and mean birth weight of 1137 g wer e studied. The concentrations of surfactant comp onents in epithelial lining fluid (ELF) were analyz ed, and the surfac e activity was measured using a pulsating bubble meth od. Prenat al DEX treatment increased the responsiveness to exogenous surfactant and decreased the seve rity of respiratory failure durin g the first day of life. The treatment had no effect on the concentrations of surfactant phospholipid s that were generally high. Prenat al DEX treatment incr eased the association between phospholipid conc entration in ELF and the degre e of respir atory failure . Prenatal DEX improved the surface activity of surfactant isolated from airway speci mens and tended to increase the ratio of surfactant protein A to phosph atidylcholin e among recipients of exogenous surfactant. A subgro up of infants , offspring of Several randomized studies have shown that prenatal glucocorticoid treatment before preterm delivery improves survival and decreases the incidence of RDS in preterm infants (1) . Likewise, treatment with both natural and synthetic surfactants decreases the mortality of very low birth weight infants and the severity of RDS (2) . In newborn infants with RDS, exogenous surfactant therapy improves gas exchange, functiona l recidual capacity, and dynamic compliance (3) . A retrospective analysis of surfact ant trials suggests that the combination therapy of prenatal glucocorticoid and exogenous moth ers with severe hypert ension had an abnormally low concentration of surfactant protein A and a poor outcome, despite prenat al DEX treatm ent or surfactant sub stitution. Prenatal DEX decreased the concentration of nonsedim entable proteins in ELF and decreased the inhibition of surface activity by these protein s. Our results indicate that imp roved surfactant function during the first day of life explains some of the beneficial pulm onary effects of prenatal glucocorticoid treatment in preterm infants who are ven tilator-depe ndent. (Pediatr Res 38: 676-684, 1995) Abbreviations AS, airw ay specimen CLD, chronic lung disease DEX, dexamethasone ELF, epithelial lin ing fluid Fio z, fractional inspir atory oxygen MAP, mean airway pressure PC, phosphatidylch oline PL, plac ebo RDS, respiratory distress syndrome SP-A, surfactant protein A surfactant has a favorable additive effect on gas exchange and on the requirement of ventilatory pressures (4) .
In animal experiments, glucocorticoids increase lung aeration (5), decrease surface tension of the lung extract (6) , and increase synthesis of surfactant phospholipids and surfactant proteins (7) . In ventilated animals, prenatal glucocorticoid treatment further alters the composition of the connective tissue in the lung (8, 9) without consistently increasing the alveolar pool of surfactant phospholipids (8) (9) (10) (11) (12) (13) . In studies involving preterm rabbits, reduction in the protein leak and improvement in the pulmonary function suggest that a favorable interaction exists between prenatal glucocorticoid and exogenous surfactant therapy (10, 11) .
The mechanisms explaining the beneficial effects of the combination of prenatal glucocorticoid and exogenous surfactant therapy on pulmonar y morbidity in preterm infants are PRENATAL DEX AN D SURFACfANT INDI CES 677 insufficiently known . According to a randomized mult icenter study, prenatal DEX treatment impro ved the outcom e of the preterm infants when exogenous surfactant is avail able (14) . Th e aims of the present study were to investigate how prenatal gluc ocortic oid treatment influences the acute efficacy of surfactant therapy, how prenat al glucocorticoid treatment influences the surface activity of the endogenous surfactant complex and the concentrations of surfac tant components in the ELF , and whether the surfac tant indices corre late with the degree of respiratory failur e.
METHODS
Patients. The 76 study infants were treated at the Children 's Hospital, University of Helsinki, between April 1989 and Novembe r 1991. The study infants and their mothers came from a single center and participated in the multicenter trial of prenatal DEX and exogenous hum an surfactant treatmen t (14) . Altogether 112 pregnant wo men were enrolled at the Departments I and II of Obstetrics and Gynecol ogy, University of Helsink i. These wome n delivered 138 live-born infants. Of these 138 infants, 80 [DEX 46, placebo (PL) 34] infants of 24 -34 wk of gestation with out life-thr eatening malformations required ventilatory support. Thirty-one (DEX 18, PL 13) infants born at 24 -34 wk did not requi re ventilatory support. Four of the 80 infants (DEX 3, PL 1) received only a short peri od of ventilatory support, and no aspirates are available. Thus, tracheal aspirates from 76 infants were analyzed.
Pregn ant wo men were eligible for the study if they fulfilled the entry criteria: 1) threatened preterm delivery between 24.0 and 31. 9 wk of gest ation , 2) intact fetal membranes, and 3) abse nce of chorioamnionitis, congenital fetal anomaly, or documented fetal lung maturity. After obtaining written inform ed consent , eligible pregnant women were blindly and randomly allocated to receive either DEX or PL intramuscularly. The pregnant women in the DEX gro up received 6 mg of DEX sodium pho sphate (Orad exon, Organon, Oss , The Netherlands), and those in the PL gro up received 0.9% saline, four doses at 12-h intervals over 36 h if the delivery did not take place. The treatm ent was not repeated. Th e investigators and those who provided care were unaware of the prenatal treatment allocation. The study design was approved by the ethical committees of the Children's Hospital and the Departments I and II of Obste trics and Gynecology, University of Helsinki.
Surfactant therapy and management ofrespiratory failure.
Human surfactant containing all three surfac tant prot eins (A, B, and C) was isolated from amniotic fluid (15) , and its sterili ty was docum ented as previously described (16) . Exogenous surfactant was administered to those infants who fulfilled the following criteria : 1) gestational age 24.0 -33.0 wk; 2) postn atal age 2-24 h; and 3) requir ement of mech anical ventilation and at least 40 % oxygen for the treatment of RDS. Retreatment was permitted at a minimum of 2 h after the first dose if the infant continued to require mechanical ventilation and at least 40 % oxygen. The dose of surfac tant was 90 mg in 3.0 mL of 0.9% sodium chloride. Up to four doses were permitted with in 80 h after birth (14) .
For all infants, supplemental oxygen was adjusted to maintain the arterial or transcut aneous oxygen tension within 6.5-9.1 kPa (50 -70 mm Hg); or oxygen saturation of Hb within 88 -92%, and arterial or capillary Peoz between 5.8 -7.8 kPa (45-60 mm Hg). Ventilato ry support was provid ed with a pressure-limited ven tilator (Baby-Bird, Bird Corporation, Palm Springs, CA).
RDS was defined as follows: typic al radiograph ic changes (17) , requirement of supplemental oxyge n for at least 48 h, and immature surfa ctant profile in the tracheal aspirate (low lecithin to sphingomye lin ratio and undetectable phosph atidylglycerol). The radio graphic severity of RDS in the chest rad iographs taken by the age of 12 h was graded from 1 to 5 (17) . In surfactant-treated infants, the severity of RDS was eva luated in the chest radiographs before surfactant administration . If no sign s of RDS were detect able, it was scored as O. Infant s were evaluated for CLD at the age of 28 d. CLD was defined as the requ irement of supplemental oxygen. Severe CLD was defined as the requirement of mechanical ve ntilation and supplemental oxygen. Durin g the 72 h after bir th, the ventilatory param eters and Fio z requir ement we re recorded prospect ively at 2, 6, 12, 24, 36, 48, and 72 h. Similarly, ve ntilatory parameters and the requirement of Fio-, in surfac tant-treated infant s we re recor ded before and after surfac tant administration. Severit y of respiratory failure was measured using the following index: mea n airway pressure X Fio z (MAP cm HzO X Fio z ) ' Collection ofairway specimen. During the first wee k of life, tracheal aspirates from the intubated infants were obtained daily at 24-h intervals when suctioning was deemed necessary by the nursing staff. The fixed time point of the aspirate collection was considered unethical. The first aspirate co llected within an hour after birth was used for the semiquantitative measurement of the lecithin to sphingomyelin ratio and phosphatidylglycerol. Before suctioning of the aspirate, 0.9% saline (0.5-1.0 mL) was instill ed into the intubation tube , and the infant was ventilated for a brief period. A catheter was then introduced into the airway , distal to the tip of the endotrache al tube. Any fluid in the airways was suctioned into a mucus extrac tor (UnoPlast AS , Hund ested, Denmark) within less than 20 s afte r the introdu ction of sali ne into the airway s. Afte r the procedure, 0.5-1.0 mL of sali ne was suctioned through the catheter into the mucus extrac tor, to reco ver material retained on the side wall s. As pirates containing visible blood we re not analyzed. If the aspirate co ntained no particles, another aspirate was recov ered, and the two aspirates were combined. Th e specimens were stored for a maximum of 12 h at 4°C and centrifuged at 150 X g for 10 min. Th e resulting supernata nt, called AS, was recovered and stored at -20°C.
Measurements of album in, protein s, pho spholip ids, and surface tension. SP-A was quantified in AS using a two-site immunoassay with two different MAb (18) . Total nonsedimentable protein was measur ed by a modified Lowry method (19) . Albumin was measured with a single radi al immunodiffusion using LC-P artigen and VLC-Partigen (Behrin gwerke AG, Marburg, Germany). The concentration of PC and saturated PC in AS was measured as described elsewhere (20) . The lecithin to sphingomyelin ratio and phosphatidylglycerol were isolated by a two-dimensional thin-l ayer chromatograph y and quantitated by planimetry (21) . The molecular weight distribution of the nonsediment able protein fraction was analyzed using gel electrophoresis. Protein electrophores is was performed in 10% SDS-polyacrylamide gel under nonreducing conditions.
The measurements of surface tension were performed at 3rC in humidified air in 150 mmol/L NaCI, 1.5 mmol/L CaCl z , and 10 mmol/L Tris-CI (pH 7.4). The pulsating bubble surfactometer was used (22) . The bubble radius of 0.40 mm was maintained for 15 s. Thereafter, the radius was varied between 0.40 and 0.55 mm at a frequency of 0.33 Hz for 5 min. The pressure difference (~P) across the surface was continuously recorded. The minimum surface tension (Ymin), i.e. the surface tension at a minimum bubble radius was calculated according to the law of Young and LaPlace:~P = 2 X y/radius. The rate of surface adsorption was estimated as follows: the bubble, radius 0.40 mm, was created and maintained while the surface tension was recorded. The rate of surface adsorption illustrates the decrease of surface tension from 71 mN/m toward equilibrium surface tension. Surface tension attained 1 s after formation of the bubble was reported. The so-called equilibrium surface tension reported is surface tension reached 5 min after formation of the bubble.
Trach eal aspirates were studied for their components and their capacity to decrease surface activity. The surfactant rich fraction was isolated by centrifugation (16 000 X g during 60 min). The pellet was suspended to 150 mmol/L NaCI, 1.5 mrnol/L CaCl z , 10 mrnol/L Tris-Cl (pH 7.4) and washed by centrifugation. The conce ntration of PC in the sedimentable fraction was adjusted to 2 f.Lmol/mL. For the measurement of the surfactant inhibit or, the nonsedimentable fraction was isolated as follows: supernatant obtained after the sediment ation of the surfactant fraction was recovered. To remove the small particles of surfactant, the supernatant was further centrifuged (40 000 X g during 120 min). The new supernatant, called nonsedimentable fraction , was concent rated using a Centricon 3 microconcentrator (cutoff 3 kD; Amicon, Beverly, MA). The concentration of protein in the nonsediment able fraction was adjusted to a final concentration of 4 g/L by adding 150 mmol/L NaCI, 1.5 mmol/L CaCl z , 10 mmol/L Tris-CI (pH 7.4). Thereafter, the nonsedim entable protein fraction was added to human surfactant isolated from amniotic fluid (15) to a final PC concentration of 1.8 mmol/L, and the specimen was incubated for 10 min at 37°C before measurement of surface activity. All surface tension measurements were performed in duplicat e.
Measurement of the concentrations in the epithelial lining fluid. The concentrations of PC, SPC, SP-A, nonsedimentable protein, and nonsedim entable albumin in ELF were calculated using urea as a marker of the extracellular space (20, 23) . Urea was quantified in plasma (recovered within 24 h from the AS) and in the nonsedim entable fraction of AS using an enzymatic method (Unimate5 urea, Roche, Basel, Switzerland). The concentration of PC was calculated as follows : [PC]ELF = [PC]AS X ureaserum/ureaAS' Uncorrected value of PC is presented as [PC] AS that corrected for ELF as [PC]ELF' Ratios of albumin in ELF to albumin in serum are presented for neonates from whom serum samples were recovered within 24 h from the AS.
The measurements were validated. Study of preterm rabbits at birth revealed that there is a close correlation (r = 0.914) between the direct measurement of PC concentration in ELF and the indirect measurement of PC concentration in ELF using the urea method (20) . To further document the validity of the present method, eight young rabbits (weight 900-1100 g) were studied. These animals were intubated and ventilated. The respiratory failure and surfactant deficiency was induced by broncho alveolar lavage, as described (24) . Four rabbits received homologous surfactant intratrache ally (100 mg/kg in 4 mLlkg saline) for the treatment of respirato ry failure. Two hours after the exogenous surfactant or placebo (air), the tracheal aspirate was collected as described above. After 'the tracheal aspirate collection, in situ bronchoalveolar lavage was performed as follows : the animal was disconn ected from the ventilator and 5 mLlkg normal saline was introduced into the airways as a bolus. Any fluid that could be recovered was withdrawn by gentle suctioning within 10 s. The concentrations of PC in ELF, calculated by the urea method were as follows (mean ± SEM): lavaged animals: tracheal aspirate collection 2.1 ± 0.3 mmol/L; bronchoalveolar lavage 2.6 ± 0. Presentation of results. After 4 d, because of extubation or death of the infants, aspirates were available from <25 % of the neonates in the DEX group and from < 50% of the neonates in the PL group. Therefore, the concentrations of PC, saturated PC, SP-A, albumin, and total nonsedimentable protein in ELF are shown from the specimens collected during the 4 d after birth. If more than one specimen from each infant was available, the mean of these is presented. For the measurement of surface activity and the inhibition of/surface activity of human surfactant by nonsedimentable pro~ins, specimens from d 2 to 4 were combined. Forty-nine specimens from 73 infants (DEX 40, PL 33) were studied for the surface activity of sedimentable lipid-prot ein complex and 43 specimens from 65 infants (DEX 32, PL 33) for the inhibition of surface activity by proteins. In the analysis of molecular weight distribution of the nonsedimentable protein, six specimens of DEX-treated infants and six specimens of PL-treat ed infants were available.
Specimens of all DEX-and PL-treated neonates were compared. The first subset analysis was performed on neonates who received exogenous surfactant. In this subgroup analysis of surfactant-treated infants, only postsurfactant specimens were analyzed. The second subset analysis was performed dividing neonates into subgroups based on prenatal treatment (DEX or PL), maternal hypertension (yes or no), and surfactant therapy (yes or no). Ventilatory parameters of all infants and of surfactant-treated infants were compared. Regression analysis was used to study correlation between the severity of respiratory failure and the concentrations of surfactant compone nts.
Multiple regression analysis was used to study the association between perinatal variables (gestational age, gender, prenatal treatment, and maternal hypertension) and neonatal outcome. Multiple regression analysis was further used to study the association between the surfactant indices and the following factors: gender, prenatal treatment (DEX or PL), maternal hypertension (yes or no) and exogenous surfactant therapy (yes or no). Maternal hypertension was defined as a severe pregnancy induced hypertension with or without proteinuria or as a chronic hypertension requiring antihypertensive therapy before pregnancy.
Statistics. The statistical analyses were performed using StatView software (Abacus Concepts Inc., 1987, Berkeley, CA). t test, analysis of variance, y test with continuity correction, and regression analysis were used. A p value <0.05 was considered significant. Results are presented as means ± SEM unless otherwise mentioned. Because of multiple comparison, the likelihood that some of the differences between the DEX and PL groups have arisen by chance is higher than indicated by the p values shown.
RESULTS
Neonatal outcome and severity of respiratory failure. Seventy-six ventilator-dependent neonates born at 24-34 wk of gestation were studied. This was 71% of all neonates born at 24-34 wk of gestation and 95% of all neonates requiring ventilatory support. Clinical characteristics of the neonates are presented in Table 1 . The DEX-treated neonates were more often males and tended to have a lower birth weight than the neonates in the PL group (Table 1) . Prenatal DEX treatment was associated with a lower rate of RDS and a lower requirement of exogenous surfactant therapy compared with prenatal PL treatment (Table 1) . However, outcome at 28 d of age did not differ significantly between the groups (Table 1) . Low gestational age, male sex, and maternal hypertension correlated with poor neonatal outcome. In the multiple regression analysis, low gestational age (p = 0.0001), male sex (p = 0.021), and maternal hypertension (p = 0.043) were associated with death or severe CLD at 28 d. Low gestational age (p = 0.0001) and maternal hypertension (p = 0.043) were associated with CLD or death at 28 d.
Neonates treated with DEX and surfactant had a mean gestational age of 28.7 wk and those treated with PL and surfactant 29.1 wk. In the DEX group, the first dose of surfactant was given at the postnatal age of 3.8 h and in the PL group at the postnatal age of 3.0 h (p = 0.14). In each group, the Studying all neonates during the 24 h after birth, the DEXtreated neonates required less ventilatory support and supplemental oxygen than the PL-treated neonates (Fig. 1) . Thereafter, no significant difference between the DEX and PL groups was noticed. Before the first dose of surfactant, the requirement of supplemental oxygen or ventilatory support did not differ significantly between the DEX and PL groups (Fig. 2) . During 24 h after the first dose of surfactant, the neonates in the DEX group required lower ventilatory pressures and less supplemental oxygen than the neonates in the PL group (Fig. 2) .
Concentrations of PC, saturated PC, and SP-A in ELF; and ratios between SP-A, PC, and saturated Pc. The concentrations of surfactant components in ELF did not differ between the DEX and PL groups, whether all infants or only surfactanttreated infants were studied ( Table 2 ). The concentrations of saturated PC in ELF did not differ between the DEX and PL groups, either (data not shown). In the specimens collected on the first day of life, concentrations of SP-A in ELF were studied in the subgroups. Infants were divided into subgroups based on maternal hypertension, prenatal treatment, and sur- glmol (p = 0.010). In the subgroup comparisons, SP-A to PC ratios were significantly higher in the DEX group than in the DEX + hypertension group (p < 0.05), and in the DEX + surfactant than in the PL + surfactant group (p < 0.05).
The ratios of saturated PC to PC were similar in both groups (saturated PC/PC mmol X L - (Table 4) . No significant correlation was seen between the gender and the surfactant indices. On the first day of life, neither prenatal treatment, maternal hypertension, nor surfactant therapy correlated with saturated PC or PC levels in ELF (data not shown). Maternal hypertension was associated with low SP-A levels and low SP-A to PC ratios on the first day of life. Both prenatal DEX and exogenous surfactant therapy were associated with high SP-A to PC ratios during the first day of life (Table 4) . Similarly, maternal hypertension was associated with low SP-A to saturated PC ratios, and prenatal DEX and exogenous surfactant therapy with high SP-A to saturated PC ratios (data not shown). Table 3 . Among all DEX-and PL-treated infants, the ratios of SP-A to PC did not differ between the groups. In the specimens collected during the 24 h after birth, the infants in the DEX + surfactant group tended to have higher SP-A to PC ratios than the infants in the PL + surfactant group (p = 0.09). SP-A to PC ratios were similarly studied in the subgroups as were Surfactant deficiency demonstrated as low lecithin to sphingomyelin ratio and low concentration of surfactant characterize the early course of RDS. In the present study several hours after birth, the infants treated with exogenous surfactant and those with mild or no RDS had high concentrations of surfactant phospholipids in ELF. Prenatal DEX treatment had no significant effect on these concentrations. Despite this, the DEX-treated infants had less severe respiratory failure, fewer infants required surfactant for the treatment of RDS, and those treated with surfactant had a more striking decrease in the severity of respiratory failure during the the first day of life than the PL-treated infants. According to one interpretation of the present results, the beneficial effects of prenatal DEX on the incidence and severity of respiratory failure may seem to be unrelated to the surfactant system.
In studies using lung explants, glucocorticoids increase the synthesis of surfactant phospholipids (7) . However, results of most in vivo studies differ from those of in vitro. Prenatal glucocorticoid treatment has increased the concentrations of total and saturated surfactant phospholipids in some unventilated fetal animals (10, 25) , but not in all (8, 9) . After mechanical ventilation, prenatal glucocorticoid treatment has had no consistent effect on the size of the total or saturated alveolar phospholipid pool in preterm rabbits or sheep (10, 12, 13) . Our results indicate that prenatal steroid treatment influences the surfactant system at birth by means other than increasing the DISCUSSION from the infants treated with PL and surfactant. In the equilibrium surface tension or in the surface adsorption, no detectable difference was seen between the DEX and PL groups (data not shown).
The inhibitory effect of the nonsedimentable protein, at a constant concentration of 4 g/L, on the surface activity of human surfactant was further studied (Fig. 4, Table 6 ). On the first day of life, the minimum surface tension of human surfactant in the presence of the nonsedimentable protein was significantly lower in the DEX-than in the PL-treated infants (Fig. 4) . The nonsedimentable protein from the Pl.-treated infants inhibited the surface adsorption more than the protein from the DEX-treated infants (Table 6 ). After the first day of life, no difference was noted between the two groups for any of these parameters.
Correlation between PC in ELF and respiratory failure.
The association between the surfactant indices and the severity of respiratory failure, expressed as MAP X Fi0 2 (em H 2 0 ), was further studied. The hypothesis tested was whether during early life there are differences in the association between the surfactant indices and the severity of respiratory failure when infants treated with DEX or PL are compared. On the first day of life, among the DEX-treated infants, the concentration of PC was associated with the degree of respiratory failure as follows: 
Concentration of total nonsedimentable protein in ELF.
The concentration of the total nonsedimentable protein in ELF is presented in Figure 3 . On the first and second day of life, the DEX-treated infants had a lower concentration of protein in ELF than the PL-treated infants regardless whether all infants or only the surfactant-treated infants were studied. Thereafter, the protein concentrations did not differ between the groups. In specimens recovered during the first day of life, the molecular weight distribution did not differ between the DEX and PL groups (data not shown).
The ratio of albumin in ELF to albumin in serum was lower in the DEX-than in the Pl.-treated infants in specimens collected on the first day of life. This was evident if all infants ([albumin]ELF/[albumin]scrum g X L-I/g XL-I: DEX 0.22 ± 0.02; PL 0.43 ± 0.11; p = 0.046) or if only the surfactanttreated infants (DEX 0.18 ± 0.03; PL 0.54 ± 0.17; p = 0.041) were studied. The ratio of albumin to total nonsedimentable protein in AS was similar in the DEX and PL groups (data not shown).
Surface activity of endogenous surfactant complex and effect of nonsedimentable protein on surface activity of human surfactant in vitro.
The surface activity of the endogenous surfactant complex isolated from AS was studied (Table  5 ). In the present in vitro conditions, less than 10% of all specimens were surface active (i.e. minimum surface tension <10 mN/m). In contrast, the surfactant used for the treatment of RDS was always surface active. On the first day of life, the DEX-treated infants had a significantly lower minimum surface tension of the sedimentable lipid-protein complex than the PL-treated infants. The endogenous surfactant complex, from the infants treated with DEX and surfactant, had a significantly lower minimum surface tension than the surfactant complex 682 KARl ET AL. (n = 10) (n = 12) (n = 7) (n = 10)
Ta ble 5. Minimum surface tension of surfactant complex isolated fro m AS
The minimum surface tension was recorded after S-min pulsation of the bubble. The phosphatidylcholine concentration was adjusted to 2 iLmol/mL. For the measurement of surface tension of the sedimentable lipid-protein complex specimens of 1 to 5 infants were combined.
, p = 0.014 compared to DEX group. t p < 0.02 compared to DEX + surfactant group. pool size or the concentr ation of surfactant phospholipid s in ELF. Glucocort icoids may affect the alveolar pool size of surfactant proteins. In studies using human fetal lung explant, glucocortic oids have both a stimulatory and an inhibitory effect on the SP-A synthesis: low doses and short exposure stimulate, whereas high doses and long exposure inhibit the synthesis of SP-A (7). Furthermore, prenatal glucocorticoid treatment increases the expression of SP-A in the whole lung of the rat fetus (26) , and prenatal glucocorticoid treatment combined with TSH-releasing hormone or fetal intervention s increases the alveolar pool size of SP-A in ventilated preterm sheep (12, 27) . In the present study, prenatal glucocorticoid administration tended to increase the ratio between SP-A and PC on the first day of life. The increase in SP-A to PC ratio after prenatal DEX treatment was significant in infants who had received SP-A-containing exogenous surfactant within 24 h and who were offspring of mothers without hypertension. On the basis of the high SP-A relative to PC after surfactant administration in DEX-treated infants, we propose that prenatal DEX treatment delays the clearance of SP-A from ELF.
Offspring of mothers with hypertens ion had low SP-A concentrations in ELF and low SP-A to PC ratios, despite prenatal DEX and surfactant treatment; these infants had also a poor neonatal outcome. Previously , it has been demonstra ted that the ratio of SP-A to saturated PC in the amniotic fluid in the severe preeclamp sia is higher than in the normal pregnancy (28) . Present results may indicate that the preterm offspring of mothers with hypertension have abnormally high catabolism or clearanc e of SP-A. In addition, our results are consistent with the previous findings that low SP-A levels in preterm or term neonates are associated with severe respirator y failure (29) and later with death or CLD (20, 30) .
Based on in vitro studies, surfactant proteins have been shown to have several functions. SP-A down-r egulates surfactant phosph olipid secretion (31) and stimulates phospholipid uptake by type II pneumocytes (32) . It has immunomodulatory properties that improve the macrophage defense against microorganisms (33). Further, this protein protects the surfactant complex against inhibitors of surface activity (34, 35) and inhibits conversion of surfactant subtyp es from large aggregate forms to small aggregate forms (36) . Surfactant proteins Band C, present in natural surfact ants, enhance the surface activity of surfactant phospholipid s (37) .
In the alveoli, surfactant complex exists in several subtypes differing in their density characteristics and in their ability to decrease surface tension (38) . Light subtypes are phospholip idrich, protein-po or small vesicles that are not surface active. Heavy and ultraheavy subtypes are large aggregates that contain surfactant proteins and are surface active. In the present study, the surfactant complex, isolated from AS by differential centrifugation, contained large aggregates. Both in the DEXand PL-treated infants, more than 90% of immunoreactive SP-A was recovered in the surfactant fraction. The surfactant complex, isolated from specimen s of PL-treated infants, was less surface active than the surfactant complex from DEXtreated infants. Prenatal DEX may alter the composition or intra-alveolar metabolism of the surfactant complex . Howev er, the cause of the difference in the surface activity of surfactant complex remains unknown. The human surfactant used for the treatment of RDS was more surface active than the surfactant complex isolated from AS of preterm neonates. Our results are different from those of Ikegami et at. (39) who, using an in vivo preterm animal model, demonstrated that the function of ex- Concentration of protein in non-sedimentable fraction was adjusted to 4 gIL, and final concentrati on of surfactant phosphatidylch oline was 1.8 mrnol/L. The minimum surface tension of human surfactant wi thout inhibitor, 0 rnN/m, was reached withi n 120 s after formation of the bubb le. In all except one instance, protein in specimens from 2 to 8 infants was combined.
* p < 0.05, other compariso ns NS.
ogenous surfactant is improved in the preterm lung. Differences in the recipient characteristics and in the exogenous surfactants between our study and the study of Ikegami et al. (39) could explain the apparently contradictory results. DEX-treated infants had a lower concentration of nonsedimentable protein in ELF and a lower ratio of albumin in ELF to albumin in serum than did PL-treated infants. Th is suggests that prenatal DEX treatment decreases alveolar-capillary permeability. High alveolar capillary permeability shortly after birth is characteristic of acute lung injury seen both in preterm animals and preterm infants with RDS (40) (41) (42) . In ventilated animals, both prenatal steroid treatment (11, 12) and exogenous surfactant therapy have been shown to decrease the concentrations of protein in bronchoalveolar fluid (11, 43, 44) . In rabbits, the combination therapy of prenatal steroid and exogenous surfac tant decreases protein leak into alveoli or improves alveolar clearance of protein more than either treatment alone (P). Our results are consistent with the reports from animalstudies and suggest that prenatal DEX improves integrity of capillary endothelium and/or increases the clearance of the plasma-derived proteins from alveolar space.
Plasma-derived proteins have been shown to increase minimum surface tension of surfactant complex and this increase is dependent on the concentration of the inhibitor (40) . According to the present results, prenatal DEX treatment decreased the inhibition of surfactant function by proteins in ELF. The low concentration of nonsedimentable protein in ELF after prenatal DEX treatment is likely to be associated with improved surfactant function. In addition, the nonsedimentable fraction from DEX-treated infants decreased the surface activity of human surfactan t less than the same concentration of protein from PL-treated infants. In the analysis of the molecular weight distribution of the nonsedimentable fraction, no detectable differences were seen between the DEX and PL-treated infants. Thus, the cause of difference in the activity of surfactant inhibitors remains unknown.
As a result of increased surface activity, ventilatory pressures are better transmitted beyond the air-liquid interface. In the DEX-treated infants, the improv ement in gas exchange, the reduction in lung edema, and the lower ventilatory requirements after surfactant treatment may in part be due to improved surfactant function. Concentrations of PC in ELF correlated inversely with the degree of respiratory failure in the DEXtreated infants but not in the PL-treated infants. Despite adequate surfactant concentration, many PL-treated and some DEX-treated infants had moderate to severe respiratory failure.
Th is suggests that functionally poo r surfactant as well as other factors such as poor distribution of surfactant, high permeability lung edema, or deficient clearance of the lung fluid may contribute to the severity of the respiratory failure. As judged on the basis of the chest radiographs, prenatal DEX treatment was associated with improved aeration and less severe lung edema than prenatal PL. The decrease in the concentration requirem ents of surfactant in ELF and the less severe pulmonary edema in chest radiographs after prenatal DEX than PL treatment may additionally indicate that prenatal DEX promotes structural maturation of the lungs in preterm infants, as has been shown in preterm animals (8, 9) .
Several factors improved the surfactant function after prenatal DEX. These include decreased concentration of protein in ELF, decreased activity of this protein to increase surface tension, increased secretion rate of surfactant at birth (assoc iated with lower incidence of RDS), and improve d intraalveolar metabolism of exogenous surfactant in RDS. However, these effects of glucocorticoid on the surfactant system and lung function remained detectable only for 1-2 d after birth. It is unclear why the period of postnatal improvement of surfactant function was apparently short-lasting and why the offspring of mothers with severe hypertension had no benefit from the therapy. There is a need to evaluate whether any new therapy or timing of therapy will further improve the neonatal transition and decrease the incidence of CLD among the high risk infants.
